Bionomics is a biotechnology business based in the US. Bionomics shares (BNOX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.01 – the same closing value as a week prior. Bionomics employs 8 staff and has a trailing 12-month revenue of around $661,980.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.01 |
|---|---|
| 52-week range | $2.12 - $15.24 |
| 50-day moving average | $3.59 |
| 200-day moving average | $7.38 |
| Wall St. target price | $9.74 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-14.32 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.01 from 2025-02-24
| 1 week (2025-03-22) | N/A |
|---|---|
| 1 month (2025-02-26) | N/A |
| 3 months (2025-01-02) | 70.99% |
| 6 months (2024-10-02) | 1,435.87% |
| 1 year (2024-04-02) | 405.86% |
|---|---|
| 2 years (2023-03-31) | -83.94% |
| 3 years (2022-04-01) | 97.86 |
| 5 years (2020-03-29) | N/A |
| Revenue TTM | $661,980 |
|---|---|
| Operating margin TTM | 8909.69% |
| Gross profit TTM | $-18,963,665 |
| Return on assets TTM | -39.58% |
| Return on equity TTM | -78.44% |
| Profit margin | 0% |
| Book value | $1.32 |
| Market Capitalization | $5 million |
TTM: trailing 12 months
We're not expecting Bionomics to pay a dividend over the next 12 months.
You may also wish to consider:
Bionomics's shares were split on a 1:12 basis on 23 December 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bionomics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Bionomics shares which in turn could have impacted Bionomics's share price.
Over the last 12 months, Bionomics's shares have ranged in value from as little as $2.124 up to $15.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bionomics's is -0.069. This would suggest that Bionomics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bionomics has bucked the trend.
To put Bionomics's beta into context you can compare it against those of similar companies.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3. 1/3. 2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1. 7/1.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.